AI Insight
Researchers have developed a method to convert standard antibodies into smaller molecules called "intrabodies" that can function inside human cells. These AI-designed intrabodies could potentially target disease-causing proteins within cells, opening new therapeutic avenues for neurodegenerative diseases including Alzheimer's, Parkinson's, Huntington's disease, and motor neurone disease. Traditional antibodies are too large to penetrate cell membranes, making this technological advancement significant for treating conditions caused by intracellular protein dysfunction.
Why it matters
This development could enable treatments for diseases that currently have limited therapeutic options, particularly neurodegenerative conditions where toxic protein accumulation occurs inside cells. The ability to deliver therapeutic molecules into cells represents a major step forward in precision medicine for conditions affecting millions of people worldwide.
Understand the Science
Researchers have developed a new way to turn ordinary antibodies into tiny disease-fighting molecules that can work inside human cells, potentially opening new paths for treating Alzheimer’s, Parkinson’s, Huntington’s disease, and motor neurone disease.
Source: AI-designed “intrabodies” could unlock new treatments for Alzheimer’s, Parkinson’s and MND